Showing results (621-630 of 1,894) with videos related to
Sort By:
Pageof 190
Alzheimer Disease and Associated Disorders|January 1, 1995
Clinical heterogeneity: responders to cholinergic therapyS A Eagger, R J HarveyAlzheimer Disease and Associated Disorders|January 1, 1995
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective propertiesS P Arneric, J P Sullivan, M W Decker, et al.Alzheimer Disease and Associated Disorders|February 24, 2006
The role of biomarkers in clinical trials for Alzheimer diseaseLeon J Thal, Kejal Kantarci, Eric M Reiman, et al.Alzheimer Disease and Associated Disorders|February 24, 2006
Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to dateRoger BullockAlzheimer Disease and Associated Disorders|February 24, 2006
The association of self-reported sleep duration, difficulty sleeping, and snoring with cognitive function in older womenShelley S Tworoger, Sunmin Lee, Eva S Schernhammer, et al.Alzheimer Disease and Associated Disorders|February 24, 2006
Early-life risk factors for Alzheimer diseaseAmy R Borenstein, Cathleen I Copenhaver, James A MortimerAlzheimer Disease and Associated Disorders|January 7, 1999
Clinical trial designs for demonstrating disease-course-altering effects in dementiaP J Whitehouse, B Kittner, M Roessner, et al.Alzheimer Disease and Associated Disorders|January 7, 1999
Frontotemporal behavioral scaleF Lebert, F Pasquier, L Souliez, et al.Alzheimer Disease and Associated Disorders|January 7, 1999
Rate of progression of mental decline in Alzheimer disease: summary of European studiesL Bracco, C Piccini, L AmaducciAlzheimer Disease and Associated Disorders|January 7, 1999
Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer diseaseA Kurz, M Riemenschneider, K Buch, et al.Pageof 190